Ernexa TherapeuticsERNA -5.30%30 Current Ratio is 2.89 as of Mar. 2026, which is 90% above its 10-year median of 1.52. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Ernexa Therapeutics ranks worse than 59.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ernexa Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 2.89.
Ernexa Therapeutics has a current ratio of 2.89. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ernexa Therapeutics's Current Ratio or its related term are showing as below:
ERNA'
s Current Ratio Range Over the Past 10 Years
Min: 0.21 Med: 1.52 Max: 6.82
Current: 2.89
During the past 6 years, Ernexa Therapeutics's highest Current Ratio was 6.82. The lowest was 0.21. And the median was 1.52.
ERNA's Current Ratio is ranked worse than 59.07% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs ERNA: 2.89
Ernexa Therapeutics (NAS:ERNA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ernexa Therapeutics Current Ratio Related Terms
Ernexa Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Ernexa Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERNA vs PMCB, SYBX, ASBP: Current Ratio Comparison
For the Biotechnology subindustry, Ernexa Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ernexa Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ernexa Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ernexa Therapeutics (ERNA) has a Current Ratio of 2.89 as of Mar. 2026. This is 90% above median its historical median of 1.52. Over the past decade, Ernexa Therapeutics' Current Ratio has ranged from 0.21 to 6.82. According to the industry distribution chart, Ernexa Therapeutics ranks #834 out of 1412 companies in the Biotechnology industry, placing it in the top 59.1%.
Is Ernexa Therapeutics' Current Ratio too high?
Ernexa Therapeutics' current Current Ratio of 2.89 is 90% above median its 10-year median of 1.52. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 6.82. The Biotechnology industry median Current Ratio is 3.89. Ernexa Therapeutics' value of 2.89 is 25.7% below this industry median. Based on the distribution chart, Ernexa Therapeutics ranks #834 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Current Ratio compare to PMCB and SYBX?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #834 out of 1412 companies for Current Ratio. This places Ernexa Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.89. Ernexa Therapeutics' value of 2.89 is 25.7% below this benchmark. Historically, Ernexa Therapeutics' own Current Ratio has ranged from 0.21 to 6.82 over the past decade. While the company's 10-year median is 1.52 vs. the industry median of 3.89, Ernexa Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ernexa Therapeutics's current Current Ratio of 2.89 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ernexa Therapeutics's current Current Ratio is 2.89, which is 90% above median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Current Ratio of 2.89. The current Current Ratio is 2.89, which is 90% above median its 10-year median of 1.52 and 25.7% below the Biotechnology industry median of 3.89. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Current Ratio is 2.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score
Get the complete analysis for ERNA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERNA has been successfully added to your 
